Literature DB >> 9031878

Ceftibuten concentrations in human tonsillar tissue.

F Scaglione1, J P Pintucci, G Demartini, S Dugnani.   

Abstract

In a study designed to determine ceftibuten concentrations in tonsillar tissue, subjects scheduled to undergo tonsillectomy were administered 400 mg of ceftibuten in a single oral dose. Between 2 and 24 h after the dose was given, tonsillar tissue samples were taken during surgery and assayed for ceftibuten. Mean concentrations in tonsillar tissue 4.4 h and 24.6 h after the 400 mg dose were 5.3 +/- 2.7 and 0.3 +/- mg/g, respectively. Concurrent mean serum concentrations were 7.42 +/- 1.66 and 0.15 +/- 0.13 mg/ml, respectively. The apparent half-life of drug in the tissue was 5.3 h. The presence of high ceftibuten concentrations in tonsillar tissue suggests that a once-daily regimen may be effective in treating tonsillitis and pharyngitis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9031878     DOI: 10.1007/bf01690513

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

1.  Penicillin V and rifampin for streptococcal pharyngitis.

Authors:  I Brook
Journal:  J Pediatr       Date:  1985-11       Impact factor: 4.406

2.  Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

Review 3.  Impact of the antibiotic dosage schedule on efficacy in experimental soft tissue infections.

Authors:  A U Gerber
Journal:  Scand J Infect Dis Suppl       Date:  1990

4.  The pharmacokinetics of ceftibuten in humans.

Authors:  W H Barr; C C Lin; E Radwanski; J Lim; S Symchowicz; M Affrime
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Jan-Feb       Impact factor: 2.803

5.  Ceftibuten and bactericidal kinetics. Comparative in vitro activity against Enterobacteriaceae producing extended spectrum beta-lactamases.

Authors:  A Bauernfeind
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Jan-Feb       Impact factor: 2.803

6.  Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany.

Authors:  A Bauernfeind
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Jan-Feb       Impact factor: 2.803

7.  Erythromycin therapy for group A streptococcal pharyngitis. Results of a comparative study of the estolate and ethylsuccinate formulations.

Authors:  C M Ginsburg; G H McCracken; S D Crow; B R Dildy; G Morchower; J B Steinberg; K Lancaster
Journal:  Am J Dis Child       Date:  1984-06

8.  Postantibiotic effect of ceftibuten on respiratory pathogens.

Authors:  N X Chin; H B Huang; H C Neu
Journal:  Pediatr Infect Dis J       Date:  1995-07       Impact factor: 2.129

9.  Ceftibuten vs. penicillin V in group A beta-hemolytic streptococcal pharyngitis. Members of the Ceftibuten Pharyngitis International Study Group.

Authors:  M E Pichichero; S E Mclinn; W M Gooch; W Rodriguez; J Goldfarb; B E Reidenberg
Journal:  Pediatr Infect Dis J       Date:  1995-07       Impact factor: 2.129

Review 10.  Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

View more
  1 in total

1.  Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibuten, cefixime and azithromycin.

Authors:  F Scaglione; G Demartini; S Dugnani; M M Arcidiacono; J P Pintucci; F Fraschini
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.